Potential Anti-Tumor Activity of Kefir-Induced Juglone and Resveratrol Fractions Against Ehrlich Ascites Carcinoma-Bearing BALB/C Mice

Erhan Bozkurt, Emre Atay, Gökhan Pektaş, Ayşe Ertekin, Ayhan Vurmaz, Ömer Adil Korkmaz, Gökhan Sadi, Esra Aslan, Öğuz Han Koca and Mehmet Bilgehan Pektaş

Abstract

We investigated the potential influence of kefir-induced juglone and resveratrol fractions (JRK) against Ehrlich Ascites Carcinoma (EAC) bearing BALB/c male mice. Kefir yeast was grown in the cell culture supplemented with juglone and resveratrol (1:2). After 48 h incubation, JRK solution was applied (0.1 mL/day i.p.) to the EAC-bearing mice throughout five days. Molecular regulatory mechanisms of apoptotic and anti-apoptotic pathway components were evaluated in the plasma of mice and isolated EAC cells with ELISA, qRT-PCR, and immunocytchemical experiments. EAC-induced upregulation in Bcl-2 and downregulation in Caspase-3 were normalized with JRK in the plasma of mice. Additionally, JRK upregulated the expression levels of apoptotic Bax, p53, Caspase-3,8,9, and APAF-1 proteins together with BAX, CASPASE-8, and CASPASE-9 genes in isolated EAC cells. These changes were also associated with decreased expression levels of anti-apoptotic Bcl-2 and Bcl-xl proteins. Immunocytochemical studies also confirmed the activation of apoptotic pathways and repression of anti-apoptotic proteins in EAC cells with JRK treatment. JRK activates apoptotic pathway and inhibits anti-apoptotic genes and proteins in Ehrlich ascites carcinoma-bearing BALB/c mice that could be beneficial in cancer treatment.

Keywords: Juglone; Resveratrol; Kefir; Ehrlich ascites; Bax; Bcl-2; p53; Caspase.

* Corresponding author:
E-mail: emreatay@gmail.com
Introduction

Cancer, a disease of genes directing the proliferation, differentiation, and the formation of cells, is the leading reason for death worldwide (1). Environmental and genetic factors determine the fate of cancer, which affects almost all body tissues, organs, and fluids (1, 2). Ehrlich Ascites Carcinoma (EAC) that could be developed from murine mammary spontaneously is modified to acidify form experimentally. This model can be kept going in outbred animals with serial intraperitoneal (i/p) passages. With their aggressive tumorigenic ability, EAC cells can rapidly proliferate and metastasize from peritoneal acid fluids to almost any body organ. Besides, they can also modulate some endogenous biochemical parameters in different body fluids, including serum and tissues (3, 4). Rodents’ peritoneal cavity might be used to passage and maintain the EAC cells, and the EAC model is recently used for tumor biology studies (5). The ability to monitor ascites carcinoma cells after injection to the animals, free neoplastic cell growing nature in abdominal fluids, and requirement of any mechanical stress for the disintegration of the cells make them as perfect cancer model for mechanistic cancer studies.

Recently, numerous bioactive compounds extracted from medicinal plants have been tested for their anti-cancer activity (6, 7). Several studies have reported the potential therapeutic effect of resveratrol (7, 8) and juglone (10-12) towards several cancer diseases. Pharmacological studies on resveratrol have reported its anti-oxidant, anti-inflammatory, anti-cancer, anti-aging, anti-obesity, anti-diabetic, cardio protective, neuroprotective, and anti-microbial properties (13). It also enhances the death of tumor cells by inhibiting Bcl-2 and upregulating Caspase-3 expression (14, 15). Furthermore, resveratrol could increase p53 and p21 by providing a balance between oxidative/anti-oxidative status (16, 17) and potentially causes cell death by inducing apoptosis. An irreversible inhibitor of the Pin1 (peptidyl-prolylcis/ trans isomerase) enzyme; juglone is a plant-originated naphthoquinone which exhibits intense anticancer activity against numerous models in-vitro (18-21). Inhibition of Pin1 triggers mitogen-activated protein kinases that could contribute the cell survival (22, 23). Moreover, it is implicated in extensive diversity of clinical circumstances including immune response (24), allergy (25), cancer (26, 27), hyperparathyroidism (28), rheumatoid arthritis (29), and cardiac fibrosis (30-32). Recent studies revealed that juglone also induces apoptosis through the pathways dependent on mitochondrial pathways by the induction of the Bax/Bcl-2 ratio (33). Likewise, juglone increased Ca²⁺ concentration and Caspase-3 activity on human breast cancer cells (34). Its anti-tumor activity is usually linked to the damages on DNA due to alkylating species or oxygen radicals (35). Potentiation of tumor necrosis factor-α (TNF-α) related apoptosis in human melanoma cells via upregulating Caspase-3, p38, and p53 were also reported (36). Although juglone and/or resveratrol were shown to have anti-cancer effects in many in-vitro studies, promising results either alone or in combination in clinical studies have not been achieved yet.

Probiotics are currently defined as nonpathogenic microorganisms that improve human health due to their anti-inflammatory and immunoregulatory properties (37). Even though their action mechanism is not well-established, it is thought to be due to their metabolic products (38). A natural complex fermented milk product; kefir contains probiotic bacteria, primarily composed of Lactobacillus, Leuconostoc, Kluyveromyces, Picha, and Saccharomyces species. It has anti-inflammatory, anti-allergenic, anti-oxidative, anti-tumor, cholesterol-lowering, constipation-lessening, and anti-microbial properties (39). Kefir also increases the anti-oxidant potential and regulates several biological processes such as apoptosis and proliferation (40, 41), and its apoptotic effects are attributed to the stimulation of Caspase-3 and Bax, repression of Bcl-2, and membrane potential reduction of mitochondria (42). Therefore, juglone, resveratrol, and kefir could have promising therapeutic potential against cancer treatments individually. However, in the current literature, there is no study showing the bioactive efficacy of combined juglone, resveratrol, and kefir solutions on cancer cell growth. Additionally,
any study demonstrated the anti-cancer effects of secondary metabolites of kefir. In this study, we hypothesized that secondary metabolites of kefir rather than the bacterial part could have therapeutically properties. We also proposed that supplementation of kefir secondary metabolites with juglone and resveratrol and their potent secondary by-products obtained during the fermentation process could have strong pharmaceutical potential for cancer cell destruction. Therefore, this study was conducted to demonstrate the potent in-vivo apoptotic and anti-apoptotic effects of kefir secondary metabolites enriched with resveratrol and juglone and their potent by-products on of Ehrlich Ascites Carcinoma cells and of EAC-bearing BALB/c mice.

**Experimental**

**Drugs and Preparation of the Solution JRK**

Chemicals for the bioassays were obtained from Sigma Aldrich (St. Louis, Missouri, USA) at the highest purity available. Juglone (H4700316) and resveratrol (EPRS-Y0001194) were dissolved in 0.1% DMSO, and the prepared mix has a ratio of 1:2, respectively. Kefir yeast contains Lactobacillus helveticus, Lactobacillus parakefiri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus fermentum, Leuconostoc mesenteroides, Lactococcus lactis, Lactobacillus kefiranofaciens, and Acetobacter pasteurianus, Bifidobacterium bifidum, Kluyveromyces marxianus, Saccharomyces cerevisiae, and Kluyveromyces lactis were obtained from Danem-Kefir (Isparta, TURKEY). The bacteria in the kefir yeast were incubated in 10 mL of broth (Difco™ Lactobacilli MRS Broth 288130) for one night at 35 °C and grown at the 1.5x10^9 cell/mL. During the fermentation process, juglone and resveratrol (200 µM-400 µM, respectively) were prepared (ethanol, <1% final concentration) and added to the broth and exposed for 48 h. The doses of juglone and resveratrol were determined according to parallel trials; resveratrol (43-45) and juglone (43, 46, 47) doses were chosen from previous in-vitro studies. Then, the solution was filtered through a 0.45 µm membrane, and the bacterial part was removed, and the remaining JRK solution was stored at -85 °C until use. The numbers of bacteria were determined with trypan blue exclusion technique with Breed method.

**Animals and Tumor Model**

Animal protocols were permitted in advance by the Local Ethics Commission for the Animal Research Studies at the Afyon Kocatepe University (AKUHADYEK-49533702.08). Male BALB/c inbred mice (18–22 g) were obtained from KOBAY A.Ş. (Ankara, TURKEY). Animals were kept growing in temperature-controlled rooms (20-22 °C) with a 12-h light-dark cycle. They were nourished with a typical rodent diet composed of 23% protein, 62% starch, 4% fat, 7% cellulose, standard vitamins, and a mixture of salt (chow pellet) and drinking water ad libitum. The EAC cells were gained from Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Anatomy (Afyonkarahisar, TURKEY). They were perpetuated with intraperitoneal (i/p) transplantation of 1x10^6 viable tumor cells in mice with a 25G needle to be used in future experimental studies. After five days of observation, JRK solution (0.1 mL/day i/p) was applied to the EAC treated mice for five days. Following the treatments, body weights and waist circumference of the mice were measured, and then ascites were isolated by a pre-scarification injector. The EAC cells’ viability was assessed with trypan blue exclusion technique (48).

**Experimental Study Design**

After acclimation for one-week, male BALB/c inbred mice were randomly separated into three groups with ten animals each. Study protocol was designed as follows; Group (1): Non-EAC-bearing mice and untreated control group (Control), Group (2): EAC-bearing mice; injected 1×10^6 viable tumor cells in 1 mL of saline (Sham), Group (3): Applied JRK solution (0.1 mL/day i/p) to EAC-bearing mice for five days (JRK). Cancer modelling lasted five days. After this period, 0.1 mL saline was injected into the control and sham groups while applying the JRK solution.

**Measurement of Apoptotic/Anti-apoptotic Biomarkers in the Plasma and EAC**

Cardiac blood and EAC samples of mice
were centrifuged immediately at 10,000 g for 30 min, and the cell pellet and supernatants were collected. Total protein levels in both plasma and EAC were determined by the Brilliant Blue G stain method using Sigma commercial kits (Saint Louis, Missouri, USA) as indicated in the package insert. The apoptotic Bax, p53, Caspase-3, Caspase-8, Caspase-9, and anti-apoptotic APAF-1 Bcl-2, Bcl-xl protein levels were determined by commercial rat specific ELISA kits (CloudClone Corp., Export Processing Zone, Wuhan, Hubei, PRC) according to the manufacturer’s instructions. ELISA microplate reader (ChemWell 2910, Awareness Technology, Inc. Martin Hwy, Palm City) was utilized for the spectrophotometric measurements.

**Determination of the Expressions Levels of Apoptotic and Anti-Apoptotic Genes**

After the animal treatments, RNA samples were isolated from the tissue and EAC cells with a commercial RNA isolation kit (Qiagen, Netherlands) along with the manufacturer procedure. Quality and quantity were assessed with spectrophotometry and electrophoresis. Thereafter, cDNA synthesis was conducted using a commercial first-strand cDNA synthesis kit (Thermo Scientific, USA). BAX, CASPASE-6, CASPASE-8, and CASPASE-9 genes expression levels were determined with quantitative real-time polymerase chain reaction (Roche, Switzerland) as we described in detail previously (49). Briefly, SYBR Green Master Mix (Roche FastStart Universal SYBR Green Master Mix), cDNA samples, and the primer pairs (Table 1) were mixed, and the qRT-PCR was conducted. Triplicate measurements were performed for each sample, and the melt analysis confirmed the specificity of PCR reactions. For the normalization of data, internal control gapdh was utilized, and the relative expression of genes was calculated by LightCycler 480 SW 1.5.1 software (Roche, USA).

**Immunocytochemical Analysis**

The suspended EAC cells were first pelleted by centrifugation at low speed for 5 min, and then, they were re-suspended in 4% formaldehyde in PBS. After warming up for 10 min at room temperature, EAC cells were pelleted again by centrifugation for 5 min at room temperature and resuspended in 80% ethanol. Fixed cells were stored at +4 °C, and then the smears were stained with immunocytochemical (ICC) staining. For ICC, immobilized cells were incubated with 0.2% Tween-20 solution for 20 min for permeability. Afterward, the slides were washed with PBS and incubated for 10 min in 3% hydrogen peroxide/methanol solution. After washing, they were incubated with Bax (sc-526, Santa Cruz Biotechnology, 1/50 dilution), Bel-2 (sc-7382, Santa Cruz Biotechnology, 1/50 dilution), p53 (sc-6243, Santa Cruz Biotechnology, 1/50 dilution), Caspase-3 (ab-4051, Abcam, 1/50 dilution) primary antibodies for 90 min. Then, HRP-conjugated secondary antibody kit (Anti-polyvalent HRP, Labvision Corp, Fremont, CA) was used to probe primary antibodies. After coloring with the chromogen, counter-staining with Mayer Hematoxylin staining was performed, and the slides were inspected using a light microscope. Cytoplasmic immunoreactivity for Bax, Bel-

| Gene      | Reverse Primer    | Forward Primer    | Gene Bank Accession Number | Product Size (bp) |
|-----------|-------------------|-------------------|---------------------------|-------------------|
| BAX       | GCTCAGCTTCTGGTGATG | CTTTTTGGCTACAGGGGGTTTCA | NM-017059.2             | 110               |
| CASPASE-6 | GACCGACTAAAACAGGCC | AATACTGTGGCCGAAATGCC | XM-008761476.2         | 246               |
| CASPASE-8 | GCTGAACCCTGTGGCCG | ACCCTGGGTGTTTATAGTTCCC | NM-022277.1           | 179               |
| CASPASE-9 | ATGTTTTCCTGTGGCACC | GTCACGGCTTGTGGAGATG | NM-031652.1           | 246               |
| GAPDH     | TCCTTGAGGGCCATGTTGGGCA | TGATGACATCAAGGAGTGGT | NM-017088.4           | 240               |
Potential Anti-Tumor Activity of Kefir-Induced Juglone

2, and Caspase-3 and nuclear and cytoplasmic immunoreactivity for p53 were considered as specific. Bax, Bcl-2, p53, and Caspase-3 expressions were calculated as the percentage of positive cells out of the total cell number at five different randomly chosen areas from each slide under 400x magnification and the data are presented as percent positive cells.

Statistical Analysis

Data are represented as mean ± standard error of the mean throughout the manuscript. Student’s t-test or one-way ANOVA followed by the Bonferroni post hoc test were utilized where appropriate to determine statistically significant differences. The level of significance was set as P values which are smaller than 0.05.

Results

The Effects of JRK Solution Body Weight, Waist Circumference and EAC Cell Viability

As shown in Table 2, Sham mice gained significantly higher weight and waist circumference than the control group (P < 0.05), whereas the terminal body weight and waist circumference of JRK-treated mice showed a tendency towards a decrease compared to Sham group.

Besides, the number of viable cells increased significantly (252.4 ± 18.4x10^6 cell/mL) in EAC cells-injected (10^6) mice at the end of the 5th day (Figure 1). Notably, JRK treatment reduced the number of viable EAC cells as compared to the Sham group (P < 0.05).

Table 2. Initial and terminal body weight (BW), the number of viable cells, and the waist circumference (WC) of the experimental groups.

| Groups | Initial BW (g) | Terminal BW (g) | WC (cm) | Cell Alive x10^6 |
|--------|---------------|----------------|---------|------------------|
| Control | 20.3 ± 0.9    | 21.8 ± 1.5     | 4 ± 0.1 | -                |
| Sham   | 20.9 ± 0.7    | 25.9 ± 1 #     | 11 ± 0.5 # | 252.4±18.4 |
| JRK    | 21.3 ± 0.4    | 25 ± 1.1       | 10.2 ± 0.4 | 119.1±7.4 * |

Values (Control n: 6; Sham n: 8; JRK n: 8) are expressed as mean ± SEM, # significantly different (P < 0.05) compared to control group; * significantly different (P < 0.05) compared to the sham group.
Figure 1. Ehrlich ascites carcinoma cells’ distributions with the trypan blue exclusion method in Sham (A) and JRK (B) groups at the end of the experiment.

Figure 2. The protein expression levels of Bax (A) Bcl-2 (B) Bcl-xl (C) p53 (D) Caspase-3 (E) Caspase-8 (F) Caspase-9 (G) and APAF-1 (H) in the EAC cells of mice. Each bar represents the means of eight mice. Values are expressed as mean ± SEM *significantly different ($P < 0.05$) compared to the sham group.
Figure 3. The mRNA expression levels of BAX (A), CASPASE-6 (B), CASPASE-8 (C), and CASPASE-9 (D) in the EAC cell of mice. Each bar represents the means of eight rats. Data were normalized by gapdh. Values are expressed as mean ± SEM, *significantly different (P < 0.05) compared to the sham group.

Figure 4. Immunocytochemical staining (x400 magnifications) (A) and quantitative analysis for the positive rate of cleaved Bax, Bcl-2, p53 and Caspase-3 expressions (B) in Sham (n = 6) and JRK (n = 7) rats. Values are expressed as mean ± SEM *significantly different (P < 0.05) compared to the sham group.
The Influences of JRK Solution in the EAC cells: Immunocytochemical Evaluation

Immunocytochemical examinations confirmed the diffuse and higher positive staining for Bax, p53, and Caspase-3 proteins in EAC cells of the JRK-treated group, but positive staining for Bcl-2 in the Sham mice (Figure 4A). As shown in Figure 4B, Bax (14.6 ± 1.4–36.5 ± 5.8), p53 (10.3 ± 2.3–26 ± 4.4), and Caspase-3 (9.75 ± 1–32.8 ± 3.1) positive rate of (%) EAC cells of JRK-treated mice were enhanced significantly compared to Sham group, whereas Bcl-2 (42.6 ± 3.3–21.5 ± 3.2) was suppressed.

Discussion

Cancer is a global problem of healthcare due to worldwide rising incidence and limited therapeutic options. Not only the ineffectiveness of treatments and side effects but also the complete remission in many cases prevents radical treatment of the disease (50). Therefore, it is essential to discover new therapeutic targets as well as new molecules with satisfying potential. Plant-derived compounds; juglone and resveratrol might be such potential therapeutic agents. Besides, dietary probiotics have also great potential for cancer prevention and treatment. Several studies have shown that juglone (10, 11, 18, 19, 33, 37, 51) resveratrol (8, 9, 12, 14-16) and kefir (41, 42) have positive effects on cancer treatment of colon, pancreas, lung, prostate, breast, and thyroid with human melanoma and myeloid leukaemia. Although the tremendous anti-cancer efficacy of the juglone through the Pin1 inhibition is well-known, its potent cytotoxic activity suppresses its selectivity (19). In this regard, taking juglone together with potent anti-oxidants would have a synergistic effect to reduce the cytotoxicity over healthy cells and to ensure appropriate pharmacotherapy (51). In this regard, we aimed to increase the selectivity of the juglone with a different strategy by investigating the effects of the end products of the kefir fermentation under juglone and resveratrol supplements.

Examination of the morphological alterations of the animals before decapitation indicated the body weight gain and waist circumference increment in the mice treated with EAC and JRK groups. This situation could be attributed to the increased intraabdominal fluid five days after the injection of EAC cells. Importantly, the number of viable EAC cells in the intraabdominal fluid from the mice in which the JRK solution is administered was reduced by more than 50% compared to the Sham group indicating the cytotoxic efficacy of JRK over EAC cells. These results are in parallel with the literature since juglone and/or resveratrol can induce apoptosis and repair DNA damage by affecting some endogenous factors. Exemplarily, juglone showed anti-cancer effect by inducing ROS/p38/p53 pathway in melanoma cells (36).

Similarly, resveratrol and kefir induced expression of Bax, while inhibiting Bcl-2, and reinforcing the expression of p53 (52, 53). However, it was determined that consumption of kefir increased caspase-3 in myeloid leukemia cells (54). These parameters and mechanisms involved in cancer pathology can induce apoptosis. Our results also demonstrated the induction of apoptotic pathways and the suppression of anti-apoptotic markers in EAC cells of the mice treated with JRK-fractions. In EAC-cells, there was a general induction of apoptotic markers; Bax, p53, Caspase-3, 8, 9 and APAF-1 with JRK application. These inductions of apoptotic markers are also evidenced with the upregulated gene expression levels of BAX, CASPASE-6, CASPASE-8, andCASPASE-9. Besides, JRK downregulated the anti-apoptotic Bcl2-xl in EAC-cells of BALB/c in plasma of male mice. The present study also revealed proapoptotic Bax, p53, Caspase-8, Caspase-9, and APAF-1 and anti-apoptotic Bcl-xl levels do not alter in the serum of Sham group. However, upregulated Bcl-2 and suppressed Caspase-3 levels in the Sham group were normalized by JRK treatment.

In general respect, mitochondrial outer membrane permeabilization is an irreversible master regulator for the entry of cells towards the death which is strongly affected by synchronizing activities of Bax and Bcl-2 family proteins. Following the changes in membrane permeability, cytochrome C is released to the cytoplasm to activate particular proteases triggering apoptosis together with the APAF-1 association. In this process,
while Bax potentially activates the apoptosis, Bcl-xl suppresses it by interacting with Bax (55, 56). Besides, cellular stress can also stimulate apoptosis via acetylation of p53 protein, which arrests the cell cycle under normal circumstances. Upon acetylation, p53 activates downstream proapoptotic target genes such as BAX. As a family of cysteine proteases and the master mediators of apoptotic cell death, Caspases are activated through cytochrome C release together with APAF-1 oligomerization (57, 58). Caspase-8 and Caspase-9 are initially activated with the cytochrome C and then lead to the proteolytic activation of other downstream proteases such as Caspase-3 and Caspase-6 which eventually shut down cellular functions by cleaving many proteins during the programmed cell death (59). The EAC modelling that we create shows first i/p distribution and systemic changes become apparent after a certain period; therewithal, we have set 10 days between the first injection and decapitation. There might have been any change in the subcomponents in the mechanism of apoptosis in the plasma. The modelling and the treatment that we applied cause changes in the essential apoptotic proteins; Bcl-2 and Caspase-3. This result means that systemic changes are in the initiation phase. In this context, JRK treatment decreased the anti-apoptotic Bcl-2 level and increased the apoptotic Caspase-3 level, which is a necessary consequence. In EAC cells, the proapoptotic factors; Bax, p53, Caspase-3, 8, 9 increased and anti-apoptotic Bcl-xl and Bcl-2 protein levels decreased in a synchronized way. These changes might induce the process leading to cell death. Although we used the JRK solution for the first time, other supporting literature information is available with that we can compare results. Firstly, resveratrol augmented the expression of apoptotic genes such as P53, BAX, CASPASE-3, and CASPASE-8 and promoted apoptosis with a pathway depending on mitochondria in breast cancer modelling (60). Similarly, resveratrol inhibited tumor angiogenesis as demonstrated by the reduction of microvessel density by vascular endothelial growth factor (VEGF) and VEGF receptor type-2 in the EAC-bearing mice (61). Moreover, juglone hindered EAC cells with reduced p-Akt levels (62). Another study presented the enrichment of BAX, CASPASE-3, CASPASE-8, and CASPASE-9 with juglone to inhibit the growth of breast cancer cells (63). Similarly, in our study, JRK solution amplified BAX, CASPASE-6, CASPASE-8, and CASPASE-9 gene expressions as compared to Sham, which is in line with the change of their protein levels. Furthermore, the positive rate of the EAC cell line was examined by immunostaining of Bax, Bcl-2, p53, and Caspase-3. Staining of proapoptotic proteins Bax, p53, and Caspase-3 appear an increase following JRK-treatment, which is a probable compensatory mechanism against reduced Bcl-2. These results appear to be consistent with the protein and gene expression results of the measured parameters of the apoptotic mechanism.

**Conclusion**

In conclusion, in this study, we highlighted the role, and the associated molecular mechanisms of JRK solution in cancer treatment, by mainly focusing on apoptotic mechanisms in EAC-bearing BALB/c mice. Even though this first stage study demonstrated that JRK is beneficial in cancer treatment and might be useful in clinical therapy, it necessitates additional clinical evidence. Further studies should be performed to determine the chemical composition of JRK solution, the secondary metabolites of kefir fermentation, juglone and/or resveratrol derivatives that might be formed through the fermentation process. To understand concrete molecular alterations of EAC and favourable effects of JRK, further studies should focus on the identification of JRK solution composition, long term, and dose-dependent response to JRK and determine survival rate and time.

**Acknowledgments**

The authors would like to appreciate Danem-Kefir (Isparta, TURKEY) for providing kefir. We are also grateful to Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Anatomy (Afyonkarahisar, TURKEY) for providing the EAC cells.
References

(1) Torres G, Zakhayry SM and Leheste JR. An evolutionary perspective of neoplastic diseases in the universe. *Cureus* (2019) 11: e4030.

(2) El-Far M, Salah N, Essam A, Abd El-Azim A, Karam M and El-Sherbiny IM. Potential anticancer activity and mechanism of action of nano formulated curcumin in experimental Ehrlich Ascites Carcinoma-bearing animals. *Nanomedicine (London)* (2019) 14: 553–73.

(3) Eisa NH, Said HS, ElSherbiny NM, Eissa LA and Torres G, Zakhary SM and Leheste JR. An evolutionary perspective of neoplastic diseases in the universe. *Cureus* (2019) 11: e4030.

(4) Verma AS, Singh A, Mallick P and Dwivedi PD. Cysteine supplementation mitigates the toxicity associated with antitumor therapy of Ehrlich’s ascites fluid adsorbed over protein containing Staphylococcus aureus Cowan I. *J. Pharm. Bioallied. Sci.* (2018) 11: 23–32.

(5) Mishra S, Tamta AK, Sarker R, Desingu PA, Verma AS, Singh A, Mallick P and Dwivedi PD. Cysteine supplementation mitigates the toxicity associated with antitumor therapy of Ehrlich’s ascites fluid adsorbed over protein containing Staphylococcus aureus Cowan I. *J. Pharm. Bioallied. Sci.* (2018) 11: 23–32.

(6) Gupta M, Mazumder UK, Kumar RS, Sivakumar T, Kumar S, Khan D, Raghavan SC and Sundaresan NR. Subcutaneous injection of curcumin against Ehrlich Ascites Carcinoma-bearing animals. *Nanomedicine* (2015) 94: 177–84.

(7) Tanveer M, Nazar U, Nazar A, Ahmad A, Siddiqui M, Ahmad T and Suzuki YJ. Juglone in oxidative stress- and mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. *OncoTarget* (2017) 8: 20895–908.

(8) Bortolotti C, Kunit T, Moder A, Hufnagl C, Schmidt WK. Juglone induces cell death of Acanthamoeba species. *Exp. Parasitol.* (2015) 159: 100–6.

(9) Jordens J, Janssens V, Longin S, Stevens I, Martens E, Bultynck G, Engelborghs Y, Lescrinier E, Waelkens E, Goris J and Van Hoof C. The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis-trans isomerase. *J. Biol. Chem.* (2006) 281: 6349–57.
(24) Esnault S, Braun RK, Shen ZJ, Xiang Z, Hening E, Love RB, Sandor M and Malter JS. Pin1 modulates the type 1 immune response. PLoS One (2007) 2: e226.

(25) Esnault S, Rosenthal LA, Shen ZJ, Sedgwick JB, Szakaly RJ, Sorkness RL and Malter JS. A critical role for Pin1 in allergic pulmonary eosinophilia in rats. J. Allergy Clin. Immunol. (2007) 120: 1082–8.

(26) Fan G, Fan Y, Gupta N, Matsuura I, Liu F, Zhou XZ, Lu KP and Gélinas C. Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappa B family. Cancer Res. (2009) 69: 4589–97.

(27) Kim G, Khanal P, Kim JY, Yun HJ, Lim SC, Shim JH and Choi HS. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer. Mol. Carcinog. (2015) 54: 440–8.

(28) Nechama M, Uchida T, MorYosef-Levi I, Silver J and Naveh-Many T. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J. Clin. Invest. (2009) 119: 3102–14.

(29) Jeong HG, Pokharel YR, Lim SC, Han YP, Ma XY and Sui DY. Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway. J. Pharmacol. (2010) 645: 14–22.

(30) Liu X, Liang E, Song X, Du Z, Zhang Y and Zhao Y. Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice. Biochem. Biophys Res. Commun. (2016) 479: 109–15.

(31) Wu D, Huang D, Li LL, Ni P, Li XX, Wang B, Han YN, Shao XQ, Zhao D, Chu WF and Li BY. Novel role of Pin1 induction in type II collagen-mediated rheumatoid arthritis. J. Immunol. (2009) 183: 6689–97.

(32) Liu X, Liang E, Song X, Du Z, Zhang Y and Zhao Y. Inhibition of Pin1 reduces myocardial fibrosis and dysfunction in STZ-induced diabetic mice. Biochem. Biophys Res. Commun. (2016) 479: 109–15.

(33) Wu X, Li M, Chen SQ, Li S and Guo F. Pin1 facilitates isoproterenol-induced cardiac fibrosis and collagen deposition by promoting oxidative stress and activating the MEK1/2-ERK1/2 signal transduction pathway in rats. Int. J. Mol. Med. (2018) 41: 1573–83.

(34) Xu HL, Yu XF, Qu SC, Zhang R, Qu XR, Chen YP, Ma XY and Sui DY. Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway. Eur. J. Pharmacol. (2010) 645: 14–22.

(35) Ji YB, Xin GS, Qu ZY, Zou X and Yu M. Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway. Genet. Mol. Res. (2016) 15

(36) Powis G. Free radical formation by antitumor quinones. Free Radic. Biol. Med. (1989) 6: 63–101.

(37) Liu X, Chen Y, Zhang Y, Du J, Lv Y, Mo S, Liu Y, Ding F, Wu J and Li J. Juglone potentiated TRAIL-induced apoptosis in human melanoma cells via activating the ROS/p38/p53 pathway. Mol. Med. Rep. (2017) 16: 9645–51.

(38) Seminario-Amez M, López-López J, Estrugo-Devesa A, Ayuso-Monterro R and Jané-Salas E. Probiotics and oral health: A systematic review. Med. Oral Patol. Oral Cir. Bucal. (2017) 22: e282-88.

(39) Dimidi E, Christodoulides S, Scott SM and Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv. Nutr. (2017) 8: 484–94.

(40) Fiorda FA, de Melo Pereira GV, Thomaz-Soccol V, Rakshit SK, Pagnoncelli MGB, Vandenbergh LPS and Soccol CR. Microbiological, biochemical, and functional aspects of sugary kefir fermentation- A review. Food Microbiol. (2017) 66: 86–95.

(41) Kumar M, Naggal R, Verma V, Kumar A, Kaur N, Hemalatha R, Gautam SK and Singh B. Probiotic metabolites as epigenetic targets in the prevention of colon cancer. Nutr. Rev. (2013) 71: 23–34.

(42) Ghoneum M and Gimzewski J. Apoptotic effect of a novel kefir product, PFT, on multidrug-resistant myeloid leukaemia cells via a hole-piercing mechanism. Int. J. Oncol. (2014) 44: 830–37.

(43) Pektas MB, Turan Ö, Öztürk G, Şumlü E, Sadi G, Yıldırım OG and Akar F. High-glucose causes vascular dysfunction through Akt/eNOS pathway: Reciprocal modulation by juglone and resveratrol. Can. J. Physiol. Pharmacol. (2018) 96: 757-64.

(44) Rakic O, Kiziltepe U, Coskun B, Aslamaci S and Akar F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int. J. Cardiol. (2005) 105: 209-15.

(45) Coskun B, Soylemez S, Parlar Al, Tulga Ulus A, Fehmi Kartıçiolu S and Akar F. Effect of resveratrol on nitrate tolerance in isolated human internal mammary artery. J. Cardiovasc. Pharmacol. (2006) 47: 437-45.

(46) Chiasson VL, Munshi N, Chatterjee P, Young KJ and Mitchell BM. Pin1 deficiency causes endothelial dysfunction and hypertension. Hypertension (2011) 58: 431-38.

(47) Ruan L, Torres CM, Qian J, Chen F, Mintz JD, Stepp DW, Fulton D and Venema RC. Pin1 prolyl isomerase regulates endothelial nitric oxide synthase. Arterioscler. Thromb. Vasc. Biol. (2011) 31: 392-8.
(48) MacLimans WF, Davis EV, Glover FL and Rake GW. The submerged culture of mammalian cells: the spinner culture. *J. Immunol.* (1957) 79: 428–33.

(49) Pektas MB, Koca HB, Sadi G and Akar F. Dietary fructose activates insulin signaling and inflammation in adipose tissue: Modulatory role of resveratrol. *Biomed. Res. Int.* (2016) 2016: 8014252.

(50) Pelicano H, Carney D and Huang P. ROS stress in cancer cells and therapeutic implications. *Drug Resist. Updat.* (2004) 7: 97–110.

(51) Gaikwad S, Chakraborty A, Salwe S, Patel V, Kulkarni S and Banerjee S. Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities. *J. Biochem. Mol. Toxicol.* (2018) 32: e22176.

(52) Wang D, Gao Z and Zhang X. Resveratrol induces apoptosis in murine prostate cancer cells via hypoxia-inducible factor 1-alpha (HIF-1α)/reactive oxygen species (ROS)/P53 signalling. *Med. Sci. Monit.* (2018) 24: 8970–76.

(53) Badr El-Din NK, Shabana SM, Abdulmajeed BA and Ghoneum M. A novel kefir product (PFT) inhibits Ehrlich ascites carcinoma in mice via induction of apoptosis and immunomodulation. *BMC Complement Med. Ther.* (2020) 20: 127.

(54) Mamdooh G and James G. Apoptotic effect of a novel kefir product, PFT, on multidrug-resistant myeloid leukemia cells via a hole-piercing mechanism. *Int. J. Oncol.* (2014) 44: 830–37.

(55) Kale J, Osterlund EJ and Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. *Cell Death Differ.* (2018) 25: 65–80.

(56) Saha T, Kar RK and Sa G. Structural and sequential context of p53: A review of experimental and theoretical evidence. *Prog. Biophys Mol. Biol.* (2015) 117: 250–63.

(57) He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y. Attenuation of TNFSF10/TRA1 induced apoptosis by an autophagic survival pathway involving TRAF2 and RIPK1/RIPI mediated MAPK8/JNK activation. *Autophagy* (2012) 8: 1811–21.

(58) You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM and Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. *Mol. Cell. Biochem.* (2013) 374: 181–90.

(59) Shakeri R, Kheirrollahi A and Davoodi J. Apaf-1: Regulation and function in cell death. *Biochimie* (2017) 135: 111–25.

(60) Mirzapur P, Khazaei MR, Moradi MT and Khazaei M. Apoptosis induction in human breast cancer cell lines by the synergistic effect of raloxifene and resveratrol through increasing proapoptotic genes. *Life Sci.* (2018) 205: 45–53.

(61) El-Azab M, Hishe H, Moustafa Y and El-Awady el-S. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich Ascites Carcinoma-bearing mice. *Eur. J. Pharmacol.* (2011) 652(1-3): 7–14.

(62) Ourique F, Kviceinski MR, Felipe KB, Correia JF, Farias MS, Castro LS, Grinevicius VM, Valderrama J, Rios D, Benites J, Calderon PB and Pedrosa RC. DNA damage and inhibition of akt pathway in mcf-7 cells and Ehrlich tumor in mice treated with 1,4-naphthoquinones in combination with ascorbate. *Oxid. Med. Cell. Longev.* (2015) 2015: 495305.

(63) Jin X, Zhang Y, Zhang Z, Che D and Lv H. Juglone loaded poloxamer188/phospholipid mixed micelles evaluated in-vitro and in-vivo in breast cancer. *Int. J. Pharm.* (2016) 515: 359–66.

This article is available online at http://www.ijpr.ir